Economic outcomes of depression screening after acute coronary syndromes: The CODIACS-QoL randomized clinical trial.

ABSTRACT:

Objective

To evaluate the cost-effectiveness of screening for depression in patients with acute coronary syndrome (ACS) and no history of depression.

Methods

Cost-effectiveness analysis of a randomized trial enrolling 1500 patients with ACS between 2013 and 2017. Patients were randomized to no screening, screening and notifying the primary care provider (PCP), and screening, notifying the PCP, and providing enhanced depression treatment. Outcomes measured were Healthcare utilization, costs, and incremental cost-effectiveness ratios.

Results

7.1% of patients screened positive for depressive symptoms. There was no significant difference in usage of mental health services, cardiovascular tests and procedures, and medications. Mean total costs in No Screen group ($7440),

SUBMITTER: Ladapo JA 

PROVIDER: S-EPMC10784112 | biostudies-literature | 2021 Jul-Aug

REPOSITORIES: biostudies-literature